Trials / Sponsors / NKGen Biotech, Inc.
NKGen Biotech, Inc.
Industry · 8 registered clinical trials — 2 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Recruiting | Open-Label Extension Protocol to SNK01-AD01 Study Alzheimer Disease | Phase 2 | 2025-06-30 |
| Recruiting | Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease Moderate Alzheimer Disease | Phase 1 / Phase 2 | 2023-11-21 |
| Completed | Study of Allogeneic Blood-derived Natural Killer Cells to Evaluate Safety and Tolerability in Cancer Refractor Pathologically Confirmed Cancer Refractory to Conventional Therapy, Refractory Cancer, Metastatic Cancer | Phase 1 | 2023-08-23 |
| Terminated | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Met Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms | Phase 1 / Phase 2 | 2021-11-03 |
| Withdrawn | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advance Advanced Solid Tumor, Metastatic Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | 2021-03-01 |
| Terminated | Safety of SNK01 in Subjects With Alzheimer's Disease (ASK-AD) Alzheimer Disease, Neuro-Degenerative Disease | Phase 1 | 2021-01-06 |
| Completed | Autologous Natural Killer Cells in Subjects With Plaque Psoriasis Plaque Psoriasis | Phase 1 | 2019-07-18 |
| Completed | Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Refractory Cancer, Metastatic Cancer, Recurrent Cancer | Phase 1 | 2019-07-15 |